MasterAM, DackS, JaffeHL. Age, sex and hypertension in myocardial infarction due to coronary occlusion. Arch Intern Med1939;64:767–786.
4.
KeysA. Seven countries. A multivariate analysis of death and coronary heart disease. Cambridge, MA: Harvard University Press, 1980.
5.
DawberTR. The Framingham study; the epidemiology of atherosclerotic disease. Cambridge: Harvard University Press; 1980.
6.
The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet1994;344:1383–1389.
7.
ShepherdJ, CobbeSM, FordI, IslesCG, Ross LorimerAR, MacFarlanePW, McKillopJH, PackardCJ, . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med1995;333:1301–7.
8.
SacksFM, PfefferMA, MoyeLA, RouleauJL, RutherfordJD, ColeTG, BrownL, Wayne WarnicaJ. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med1996;335:1001–9.
9.
SchmitzG, AssmannG. Acid lipase deficiency: Wolman disease and cholesteryl ester storage disease. In: ScriverCR, BeaudetAL, SlyWS, ValleD, eds. The metabolic basis of inherited disease. 6th ed.New York: McGraw-Hill1989;1623–44.
10.
SpenceMW, CallahanJW. Sphingomyelin-cholesterol lipidoses: the Niemann-Pick group of diseases. In: ScriverCR, BeaudetAL, SlyWS, ValleD, eds. The metabolic basis of inherited disease. 6th ed.New York: McGraw-Hill1989;1655–76.
11.
KaneJP, HavelRJ. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: ScriverCR, BeaudetAL, SlyWS, ValleD, eds. The metabolic basis of inherited disease. 6th ed.New York: McGraw-Hill1989;1139–64.
12.
WetterauJR, AggerbeckLP, BoumaM-E, EisenbergC, MunckA, HermierM, SchmitzJ, GayG, RaderDJ, GreggRE. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science1992;258:999–1001.
13.
BrunzellJD. Familial lipoproteïn lipase deficiency and other causes of the chylomicronemia syndrome. In: ScriverCR, BeaudetAL, SlyWS, ValleD, eds. The metabolic basis of inherited disease. 6th ed.New York: McGraw-Hill1989;1165–80.
14.
The Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA1993;269:3015–23.
15.
MarmotMG, SymeSL, KaganA, KatoH, CohenJB, BelskyJ. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii, and California: prevalence of coronary and hypertensive heart disease and associated risk factors. Am J Epidemiol1975;102:514–525.
16.
ToorM, KatchalskyA, AgmonJ. Atherosclerosis and related factors in immigrants to Israel. Circulation1960;22:265–79.
17.
KushiLH, LewRA, StareFJ, EllisonCR, el LozyM, BourkeG, DalyL, GrahamI, HickeyN, MulcahyR. Diet and 20-year mortality from coronary heart disease. The Ireland-Boston Diet-Heart Study. N Engl J Med1985;312:811–8.
18.
RosenmanRH, FriedmanM, StrausR.WurmM, KositchekR.HahnW, Worth essenNT. A predictive study of coronary heart disease. The Westem Collaborative Group study. JAMA1964;189:15–26.
19.
ShekelleRB, ShryockAM, PaulO, LepperM, StamlerJ.LiuS, RaynorWJJr. Diet, serum cholesterol, and death from coronary heart disease: The Westem Electric study. N Engl J Med1981;304:65–70.
20.
HolmeI, SolbergLA, WeissfeldL, HelgelandA, HjermannI, LerenP, StrongJP, WilliamsOD. Coronary risk factors and their pathway of action through coronary raised lesions, coronary stenoses, and coronary death. Multivariate statistical analysis of an autopsy series; the Oslo study. Am J Cardiol1985;55:40–7.
21.
ReedD, YanoK, KaganA. Lipids and lipoproteins as predictors of coronary heart disease, stroke, and cancer in the Honolulu Heart Program. Am J Med1986;80:871–8.
22.
Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA1982;248:1465–77.
23.
GordonT, KannelWB, CastelliWP, DawberTR. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med1981;141:1128–31.
24.
CastelliWP, GarrisonRJ, WilsonPW, AbbottRD, KalousdianS Kannel, WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA1986;256:2835–8.
25.
AndersonKM, CastelliWP, LevyD. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA1987;257:2176–80.
26.
GordonT, CastelliWP, HjortlandMC, KannelWB, DawberTR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med1977;62:707–14.
27.
KannelWB. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol1983;52:98–128.
28.
HavelRJ, KaneJP. Structure and metabolism of plasma lipoproteins. In: ScriverCR, BeaudetAL, SlyWS, ValleD, eds. The metabolic and molecular basis of inherited disease. 7th edition. New York: McGraw-Hill, USA1995:1841–51.
29.
FriedewaldWT, LevyRI, FredricksonDS. Estimation of the concentraion of low density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem1972;18:499–503.
30.
PhillipsNR, WatersD, HavelRJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation1993;88:2762–70.
31.
AvinsAL, HaberRJ, HulleySB. The status of hypertriglyceridemia as a risk factor for coronary heart disease. In: RifkindBM, LippelK, eds. Clinics in laboratory medicine1989;9:153–68.
32.
AustinMA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb1991;11:1–14.
33.
HokansonJE, AustinMA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk1996;3:213–9.
34.
BassKM, NewschafferCJ, KlagMJ, BushTL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med1993;153:2209.
35.
CastelliWP. Epidemiology of triglycerides. A view from Framingham. Am J Cardiol1992;70:3H.
36.
FontbonneE, EschwegeE, CambienF, RichardJ-L, DucimetierePThibult, N, WarnetJ-M, ClaudeJ-R, RosselinG-E. Hypertriglyceridema as a risk factor for coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Diabetologia1989;32:300–4.
37.
UusitupaMIJ, NiskanenLK, SiitonenO, VoutilainenE, PyoralaK. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in Type 2 (noninsulin-dependent) diabetic and nondiabetic subjects. Diabetologia1993;36:1175–84.
38.
LaaksoM, LehtoS, PenttiläI, PyöräläK. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation1993;88:1421–30.
39.
SmithSJ, CooperGR, MyersGL, SampsonEJ. Biological variability in concentrations of serum lipids: sources of variation among results from published studies and composite predicted values. Clin Chem1993;39:1012–22.
WeberM, McNicollS, Lussier-CacanS, MarcilM, ConnellyP Rondeau, C, LatourY, DavignonJ, GenestJJr. Plasma lipoproteins, apolipoprotein B, apolipoprotein E phenotypes and metabolic factors in premature CAD in French Canadians. Can J Cardiol1997;13:253–60.
43.
ScheaferEJ, LeryRI, AndersonDW, DannerRN, BrewerHBJr, BlackwelderWC. Plasma triglycerides in the regulation of HDL. Lancet1978;2:391–393.
44.
PatschJR, MiesenböckG, HopferwieserT, MöhlbergerV Knapp, E, DunnJK, GottoAMJR, PatschW. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb1992;12:1336–45.
45.
StampferMJ, KraussRM, BlanchePJ, HollLG, SacksFM, HennekensCH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA1996;276:882–8.
46.
BenlianP, De GennesJL, FoubertL, ZhangH, GagnéSE, HaydenM. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med1996;335:848–54.
47.
NikkiläEA. Familial lipoprotein lipase deficiency and related disorders of chylomicron metabolish. In: StanburyJB, WyngaardenJB, FredricksonDS, GoldsteinJL, BrownMS, eds. The metabolic basis of inherited disease. 5th edition. New York: McGraw-Hill, 1983;622–42.
48.
BrunzellJD, SchrottHG, MotulskyAG, BiermanEL. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism1976;25:313–20.
49.
BrunzellJD, AlberssJJ, ChaitA, GruncySM, GrozekE, McDonaldGB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res1983;24:147–55.
50.
AustinMA, McKnightB, EdwardsKL, WallaceKJ, BradleyCM, McNeely MJ, BrunzellJD, MotulskyAG. Twenty-year cardiovascular disease (CVD) mortality in familial combined hyperlipidemia and familial hypertriglyceridemia: an historical cohort study [abstract]. Circulation1997;96:I-412.
51.
ChaitA, BrazgRL, TribbleDI, KraussRM. Susceptibility of small, dense low density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med1993;94:350–6.
52.
MahleyRW, RallSCJr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: ScriverCR, BeaudetAL, SlyWS, ValleD, eds. The metabolic basis of inherited disease. New York: McGraw-Hill Publishing Co1989:1195–213.
GordonT, CastelliWP, HjortlandMC, KannelWB, DawberTR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med1977;62:707–14.
55.
JacobsDR (for Lipid Research Clinics Follow-Up Study). High density lipoprotein cholesterol and coronary heart disease, cardiovascular disease and all-cause mortality. Circulation1985;72(III Suppl):185.
56.
WatkinsLO, NeatonJD, KullerLH. Racial differences in high-density lipoprotein cholesterol and coronary heart disease incidence in the usual-care group of the multiple rish factor interverntion trial. Am J Cardiol1986;57:538–45.
57.
MillerNE, ThelleDS, FordeOH, MjosOD. The Tromso heart-study. High-density lipoprotein and coronary heart disease: a prospective case-control study. Lancet1977;1:965–8.
58.
GoldbourtU, MedalieJH. High-density lipoprotein cholesterol and incidence of coronary heart disease the Israeli ischemic heart disease study. Am J Epidemiol1979;109:296–308.
59.
EngerSC, HjermannI, FossOP, HelgelandA, HolmeI.LerenP, NorumKR. High-density lipoprotein cholesterol and myocardial infarction or sudden coronary death: a prospective case-control study in middle-aged men of the Oslo study. Artery1979;5:170–81.
60.
AssmannG, SchulteH, Von EckardsteinA, HuangY. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis1996;124:S11–S20.
61.
GordonDJ, ProbstfieldJL, GarrisonRJ, NeatonJD, CastelliWP, KnokeJD, JacobsDRJr, BangdiwalaS, TyrolerHA. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation1986;79:8–15.
62.
WilsonPWF, AbbottRD, CastelliWP. High density lipoprotein cholesterol and mortality. The Framingham study. Arteriosclerosis1988;8:737–41.
63.
GoldbourtU, YaariS, MedalieJH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol1997;17:107–13.
64.
RobinsonD, FernsGA, BevanEA, StocksJ, WilliamsPT, GrattonDJ. High density lipoprotein subfractions and coronary risk factors in normal men. Arteriosclerosis1987;7:341–6
65.
StampferMJ, SacksFM, SalviniS.W'llettWC, HennekensCH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med1991;325:373–81.
66.
AustinMA, KingMC, VranizanKM, KraussRM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation1990;82:495–506.
DammerrnanM, BreslowJL. Genetic basis of lipoprotein disorders. Circulation1995;91:505–11.
69.
BreslowJL. Familial disorders of high density lipoprotein metabolism. In: ScriverCR, BeaudetAL, SlyWS and ValleD, eds. The metabolic and molecular basis of inherited disease. 7th edition. McGraw-Hill, USA1995: 2031–52
70.
CalabresiL, FrancesciniG. High density lipoprotein and coronary artery disease: insights from mutations leading to low density lipoprotein. Curr Opinion Lipidol1997;8:219–24.
71.
AssmanG, von EckardsteinA, BrewerHBJr. Familial high density lipoprotein deficiency: Tangier disease. In: ScriverCR, BeaudetAL, SlyWS and ValleD, eds. The metabolic and molecular basis fo inherited disease. 7th edition. McGraw-Hill, USA1995:2053–72.
72.
Serfaty-LacrosniereC, CivieraF, LanzbergA. homozygous Tangier disease and cardiovascular disease. Atherosclerosis1994;107:85–98.
73.
KuivenhovenJA, PritchardH, HillJ, FrohlichJ, AssmannG, KasteleinJ. The molecular pathology of lecithin: cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res1997;38:191–205.